Luminant is a strategic advisory firm dedicated to helping life science organizations navigate complexity with clarity, creativity, and analytical precision. Our work brings together corporate development, portfolio and valuation strategy, data analytics, informatics, and AI-enabled insight, allowing teams to move confidently from uncertainty toward meaningful progress.
We unite strategic business expertise with scientific and analytical insight, equipping teams to see connections others miss, illuminate pathways forward, and accelerate what comes next. At Luminant, we believe progress emerges where insight meets imagination, and we work closely with our clients to uncover the signal in the noise.
Dr. Labkoff is a physician executive and clinical informatician who applies data, technology, and analytics to healthcare and life sciences research. He advises healthcare organizations, research institutions, and life sciences companies on AI strategy, data architecture, real-world evidence, and clinical development innovation.
He most recently served as Vice President of Development and Medical Affairs Analytics at Bristol Myers Squibb, leading global data and AI initiatives across clinical trial recruitment, site selection, and operational performance, and has held senior leadership roles at Pfizer and AstraZeneca. As Chief Data Officer of the Multiple Myeloma Research Foundation, he led development of CureCloud, a direct-to-patient research platform connecting patient-generated, clinical, and genomic data.
Dr. Labkoff is a Collaborating Scientist in Biomedical Informatics at Beth Israel Deaconess Medical Center and Harvard Medical School, and has taught at Harvard Business School and the Yale School of Management. He is a Fellow of the American College of Physicians, the American College of Medical Informatics, and the American Medical Informatics Association, and serves as an advisor and venture partner to Boston Millennia Partners.
Liron Sissman is a life sciences business development and strategy executive who advises biopharmaceutical, medtech, and adjacent industries on growth, market entry, and value creation. She has held senior leadership roles in business development at biopharmaceutical companies, leading and executing approximately $2 billion in transactions across licensing, M&A, and strategic partnerships with public companies, private equity-backed organizations, and emerging ventures. Having negotiated from both the buy side and the sell side, she brings a practical sense for finding creative structures that align parties and move partnerships forward.
Through Luminant, Liron advises life science executives on growth strategy, market positioning, and business development opportunities that often extend beyond traditional deal-making, from identifying adjacent revenue streams and prioritizing new platform use cases to raising capital, modeling new businesses, and optimizing portfolios to maximize valuation. Her consulting work has included architecting a growth strategy for a rare disease-focused service that drove a significant valuation uplift and supported its acquisition by a private equity firm, and developing the strategic portfolio valuation and business case that enabled a pharmaceutical company to secure a private placement and complete a successful spinout. Liron holds an MBA in Finance and International Business from the Stern School of Business at New York University and a B.Sc. in Chemistry from The Hebrew University of Jerusalem.
Christopher Williams is a business development and alliance leader with experience in oncology, precision medicine, diagnostics, and data-enabled biopharma partnerships. He brings a combination of scientific fluency and commercial judgment to help organizations translate complex scientific and data assets into credible partnerships and revenue-generating relationships.
Most recently, Christopher worked with the Multiple Myeloma Research Foundation, where he helped shape partnerships built around clinical, molecular, and real-world data assets, working across scientific, clinical, legal, and executive stakeholders to position data-rich capabilities for biopharma collaboration. He has also held commercial leadership roles across diagnostics and regulated laboratory environments, including at PerkinElmer, Wavesense, and SkylineDx, spanning molecular diagnostics, prenatal testing, and CE-IVD product approval in Europe. Originally trained as a bench scientist, he is PMP certified and known for a disciplined, practical approach to partnership development where scientific credibility and commercial opportunity must be built in parallel. Christopher holds an M.S. in Biochemistry and a B.S. in Microbiology and Molecular Biology, both from Clemson University.